ReviewPharmaceutics2025
Advances in Second Near-Infrared Window Photothermal Agents and Photothermal Therapy for Tumors in Interdisciplinary Medical Research.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- NLS-functionalized semiconducting polymer nanoparticles for enhanced intracellular accumulation and combined photodynamic-photothermal cancer therapy.RSC advances · 2026Article
- Macrocyclic histone deacetylase inhibitor-based near-infrared-responsive ionic nanomedicines for enhanced cancer therapy.International journal of pharmaceutics · 2026Article
- Targeting ferroptosis induction via nanomaterials in hepatocellular carcinoma: an insight into mechanism and therapeutic potential.Journal of nanobiotechnology · 2026Review
- Article
- Nanotechnology in Dermatology: A Comprehensive Narrative Review of Performance, Safety, and Clinical Translation.Health science reports · 2026Article
- Recent Advances in Nanomedicine for Targeted Phototherapy in Head and Neck Cancer.International journal of nanomedicine · 2026Review
- Construction and Characterization of PDA@MnOPharmaceutics · 2025Article
- Advances in mild photothermal hydrogel-based therapies for bone and soft tissue injuries.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer continues to pose a significant threat to human health. While early diagnosis has improved survival rates for many cancer patients, a substantial number still do not achieve the desired treatment outcomes. Therefore, it is imperative to develop novel therapeutic approaches for tumor management. Second near-infrared window photothermal therapy has garnered considerable attention from researchers due to its effective tumor-killing capabilities and minimal side effects. This review commences by summarizing the advancements in second near-infrared photothermal agents, alongside an evaluation of the advantages and disadvantages of various photothermal agents. Subsequently, we highlight the benefits of combining photothermal therapy with other treatment modalities. Finally, we present a compilation of reports detailing the application of photothermal therapy in the treatment of various tumor types in clinical settings. In the conclusion, we underscore the challenges and potential research directions associated with photothermal therapy. Our article aims to facilitate interdisciplinary research in the fields of nanomedicine and clinical medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.